FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)
KEYTRUDA Now Approved for First-Line Treatment of Patients with Metastatic or with Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma as Monotherapy for Patients Whose Tumors Express PD-L1 (CPS ≥1) or in Combination with Platinum and Fluorouracil (FU) Regardless of PD-L1 Expression
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy in patients
whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) or in
combination with platinum and fluorouracil (FU), a commonly used
chemotherapy regimen, for the first-line treatment of patients with
metastatic or with unresectable, recurrent head and neck squamous cell
carcinoma (HNSCC).
Media Contacts:
Pamela Eisele
(267) 305-3558
Ayn Wisler
(908) 740-5590
Investor Contacts:
Teri Loxam
(908) 740-1986
Michael DeCarbo
(908) 740-1807
Read Original Article: FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab) »
